In a prospective study of a cohort of 1,358 community-dwelling adults, baseline prevalence of Raynaud's Phenomenon was 11% in women and 8% in men; remission rate over 7y of f/u was 64% (Arth. Rheum. 52:1259, 2005--JW)

Treatments traditionally include cold avoidance, Calcium channel blockers, Angiotensin Receptor Blockers, and topical nitroglycerin, though none of these is highly effective

Digital artery sympathectomy can relieve sx but sx frequently recur


Bosentan (an endothelin antagonist) for Raynaud's phenomenon